In patients with relapsing MS, the transition to cladribine from natalizumab is a safe and effective option that provides sustained disease stability.

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...

Among those fired in the recent spate of Trump administration cuts are staff members at the NIH's Center for Alzheimer's and ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

The FDA has also approved glatopa, a generic form of Copaxone. Natalizumab (Tysabri) is an infused medication that may block damaged T lymphocytes from entering the brain and spinal cord.

The main patents on Tysabri (natalizumab) expired in the US and Europe in February; although, various use patents claim protection until 2027 and are still in dispute. The green light from the FDA ...

and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014. That resulted in false claims for ...

as was the case for the antibody specific for very late antigen 4 (also known as α4 integrin), natalizumab (Tysabri; Biogen Idec/Elan) 22. In conclusion, we propose that PIDs may provide useful ...

The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy ...

Many DMT drugs are also approved to treat clinically isolated syndrome—this includes all of the injectable medications, many of the oral drugs, and two of the infusion drugs: Ocrevus (ocrelizumab) and ...